Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Sobi (Swedish Orphan Biovitrum AB)
Sobi (Swedish Orphan Biovitrum AB)
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Ingredients
Therapeutic: loncastuximab tesirine for diffuse large B-cell lymphoma
Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of blood cancer. Up to 40% of patients will require further lines of treatment as their disease relapses or becomes refractory to first line treatment
Ingredients
Therapeutic for paroxysmal nocturnal haemoglobinuria: pegcetacoplan
Paroxysmal nocturnal haemoglobinuria (PNH) is a rare and chronic blood disorder in which red blood cells are destroyed via extravascular and intravascular haemolysis
Finance
Sobi to acquire Synagis US rights from AstraZeneca
Synagis, the only approved respiratory syncytial virus prophylaxis for high-risk infants, complements Sobi’s expertise in paediatrics and immunology
Recruitment
Fredrik Wetterlundh joins Sobi
Pharmaceutical
Sobi establishes new leadership structure and appoints Torbjorn Hallberg as General Counsel
Pharmaceutical
Norbert Oppitz joins Sobi as new Senior VP, Specialty Care
Finance
Sobi enters into new distribution agreement with Valeant for Ammonul
The company has entered into a three-year agreement with Valeant Pharmaceuticals Ireland for the distribution in Europe, the Middle East and North Africa
Subscribe now